Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

PROTALIX BIOTHERAPEUTICS INC (PLX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
06/12/2018 06/13/2018 06/14/2018 06/15/2018 06/18/2018 Date
0.46(c) 0.456(c) 0.4496(c) 0.45(c) 0.45(c) Last
280 866 459 199 389 561 324 510 292 846 Volume
-1.08% -0.87% -1.40% +0.09% 0.00% Change
More quotes
Financials (USD)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 4,16x
Capi. / Sales2014 1,83x
Capitalization 65,5 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.The... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
06/05Protalix BioTherapeutics Announces Additional Positive Results from Final Ana..
GL
05/31PROTALIX BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form..
AQ
05/28PROTALIX BIOTHERAPEUTICS : Announces Poster Presentation on Baseline Characteris..
AQ
05/26PROTALIX BIOTHERAPEUTICS : Announces Poster Presentation on Baseline Characteris..
AQ
05/25Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteri..
GL
05/24Protalix Announces Exchange and Discharge of Remaining 2018 Notes
GL
05/14PROTALIX BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Subm..
AQ
05/09PROTALIX BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Con..
AQ
05/09PROTALIX : 1Q Earnings Snapshot
AQ
05/09PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition (..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
02:01pAlexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 1 349%
EPS Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTICS INC-31.94%66
CELLTRION, INC.--.--%33 912
IQVIA HOLDINGS INC7.13%21 394
LONZA GROUP3.38%20 435
INCYTE CORPORATION-21.91%15 677
ALNYLAM PHARMACEUTICALS, INC.-15.15%10 836